Insider Transactions in Q4 2023 at Nuvalent, Inc. (NUVL)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2023
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
48,548
-1.38%
|
$3,641,100
$75.67 P/Share
|
|
Dec 27
2023
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
1,000
-0.06%
|
$75,000
$75.17 P/Share
|
|
Dec 26
2023
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
69,602
-1.89%
|
$5,150,548
$74.67 P/Share
|
|
Dec 19
2023
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$375,000
$75.0 P/Share
|
|
Dec 19
2023
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$90,000
$18.93 P/Share
|
|
Dec 18
2023
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
40,000
-100.0%
|
$3,000,000
$75.82 P/Share
|
|
Dec 18
2023
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+29.34%
|
$280,000
$7.46 P/Share
|
|
Dec 18
2023
|
Anna Protopapas |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$375,000
$75.67 P/Share
|
|
Dec 18
2023
|
Anna Protopapas |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$45,000
$9.36 P/Share
|
|
Dec 18
2023
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-100.0%
|
$2,250,000
$75.82 P/Share
|
|
Dec 18
2023
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$30,000
$1.08 P/Share
|
|
Dec 18
2023
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
33,046
-100.0%
|
$2,478,450
$75.82 P/Share
|
|
Dec 18
2023
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,046
+50.0%
|
$892,242
$27.85 P/Share
|
|
Nov 28
2023
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
9,150
-0.25%
|
$567,300
$62.03 P/Share
|
|
Nov 01
2023
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,000
-56.47%
|
$156,000
$52.31 P/Share
|
|
Nov 01
2023
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
$3,000
$1.08 P/Share
|
|
Oct 24
2023
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
91,700
-2.37%
|
$4,585,000
$50.93 P/Share
|
|
Oct 04
2023
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
20,000
-86.5%
|
$1,120,000
$56.48 P/Share
|
|
Oct 04
2023
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+46.76%
|
$60,000
$3.99 P/Share
|
|
Oct 04
2023
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,995
-6.97%
|
$439,725
$55.01 P/Share
|
|
Oct 04
2023
|
Christopher Durant Turner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,995
+26.21%
|
$47,970
$6.89 P/Share
|
|
Oct 02
2023
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,000
-73.3%
|
$138,000
$46.12 P/Share
|
|
Oct 02
2023
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
$3,000
$1.08 P/Share
|